AIC
NBIX icon

Aurora Investment Counsel’s Neurocrine Biosciences NBIX Stock Holding History

Aurora Investment Counsel’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
8,724
-1,477
-14% -$219K 0.76% 75
2026
Q1 		$1.34M Sell
10,201
-614
-6% -$81.5K 0.75% 73
2025
Q4 		$1.53M Sell
10,815
-23
-0.2% -$3.33K 0.81% 68
2025
Q3 		$1.52M Sell
10,838
-189
-2% -$25.6K 0.8% 69
2025
Q2 		$1.39M Buy
11,027
+507
+5% +$58.1K 0.73% 74
2025
Q1 		$1.16M Buy
10,520
+138
+1% +$17.5K 0.65% 79
2024
Q4 		$1.42M Sell
10,382
-63
-0.6% -$7.79K 0.78% 67
2024
Q3 		$1.2M Buy
10,445
+8
+0.1% +$1.1K 0.65% 82
2024
Q2 		$1.44M Sell
10,437
-118
-1% -$16.2K 0.84% 68
2024
Q1 		$1.46M Sell
10,555
-3,171
-23% -$433K 0.83% 68
2023
Q4 		$1.45M Buy
13,726
+342
+3% +$39.4K 0.94% 53
2023
Q3 		$1.51M Sell
13,384
-124
-0.9% -$13.1K 1% 39
2023
Q2 		$1.27M Sell
13,508
-151
-1% -$14.8K 0.82% 64
2023
Q1 		$1.38M Buy
+13,659
New +$1.42M 0.9% 56

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aurora Investment Counsel's NBIX Position: Q2 2026 in Review

Aurora Investment Counsel reduced its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, selling an estimated $219K and leaving 8,724 shares worth $1.47M. The position accounts for 0.76% of the portfolio, ranked #75.

Aurora Investment Counsel first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.53M in Q4 2025. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Aurora Investment Counsel held 8,724 shares of Neurocrine Biosciences worth $1.47M as of Q2 2026.
  • Aurora Investment Counsel sold 1,477 Neurocrine Biosciences shares in Q2 2026, an estimated $219K.
  • Neurocrine Biosciences made up 0.76% of Aurora Investment Counsel's portfolio in Q2 2026, its #75 holding.
  • Aurora Investment Counsel first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Aurora Investment Counsel's Neurocrine Biosciences position peaked at $1.53M in Q4 2025.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Aurora Investment Counsel's 13F filing for Q2 2026, filed 10 Aug 2026.